RESEARCH: HALOGENASE-DIRECTED-DRUG-DESIGN
FOLDING PROJECT #19221 PROFILE

Many medicines use halogens (like fluorine). Adding these can be tricky, making unwanted byproducts. A project relates to using enzymes called halogenases which add halogens very precisely. By studying how these enzymes work, we hope to predict where they'll add halogens on different molecules.

Note: This TLDR is a simplication and may not be 100% accurate.

Approximately 40 percent of drugs approved or currently in clinical testing contain halogens (F, Cl, Br, or I) as pharmaceutically active ligand substituents.

This makes the halogenation of chemical scaffolds an issue of particular interest to medicinal chemists when attempting to synthesize potential drug candidates.

Many of the current methods for halogenation are difficult to control the regioselectivity or produce toxic byproducts during the reaction.

Due to these issues; halogenases, a class of enzymes that catalyze highly regioselective halogenation of various molecules in nature, have been studied as a means to improve existing halogenation methods with less toxic byproducts and higher regioselectivity of reaction.

By utilizing Relative Binding Free Energy calculations (RBFE) across a number of common organic molecule scaffolds, our goal is to better predict the probability and site of halogenation for various common chemical scaffolds across a number of halogenases.

---

halogen

Elements fluorine (F), chlorine (Cl), bromine (Br), or iodine (I).

Halogens are a group of elements known for their reactivity. They are frequently incorporated into drug molecules to modify their properties and improve their effectiveness.

---

ligand

A molecule that binds to a specific receptor or protein.

Ligands are molecules that attach to other molecules, often proteins. In drug development, ligands can be designed to bind to specific targets in the body, such as receptors involved in disease processes.

---

pharmaceutically active

Having a therapeutic effect.

A pharmaceutically active substance is one that can produce a desired medical effect when administered to a patient. This could include pain relief, lowering blood pressure, or fighting infection.

---

medicinal chemist

A scientist who designs and synthesizes new drugs.

Medicinal chemists are experts in the field of drug development. They use their knowledge of chemistry to create new molecules that have the potential to treat diseases.

---

halogenation

The process of adding a halogen atom to a molecule.

Halogenation is a chemical reaction that involves introducing one of the halogen elements (fluorine, chlorine, bromine, or iodine) into an organic molecule. This process can alter the properties of the molecule and make it more suitable for specific applications.

---

regioselectivity

The preference of a reaction to form one product over others when multiple products are possible.

Regioselectivity refers to the specific location on a molecule where a chemical reaction occurs. In drug development, it is crucial to control regioselectivity to ensure that the desired product is formed.

---

byproduct

An unwanted product formed during a chemical reaction.

Byproducts are substances produced unintentionally during a chemical process. In pharmaceutical manufacturing, it is important to minimize the formation of byproducts to ensure drug safety and efficacy.

---

enzyme

A biological catalyst that speeds up chemical reactions.

Enzymes are proteins that play a vital role in biological processes. They accelerate chemical reactions within cells by lowering the activation energy required for the reaction to occur.

---

halogenase

An enzyme that catalyzes the halogenation of molecules.

Halogenases are a specific type of enzyme that introduce halogen atoms into organic molecules. They are found in nature and have potential applications in pharmaceutical research and development.

---

Relative Binding Free Energy (RBFE)

A method for predicting the binding affinity of a molecule to a target.

RBFE calculations are used in computational drug discovery to estimate how strongly a potential drug molecule binds to its intended target. This information helps researchers select promising candidates for further development.